MX2019003585A - Derivados de tetrahidropiridina y su uso como agentes antibacterianos. - Google Patents
Derivados de tetrahidropiridina y su uso como agentes antibacterianos.Info
- Publication number
- MX2019003585A MX2019003585A MX2019003585A MX2019003585A MX2019003585A MX 2019003585 A MX2019003585 A MX 2019003585A MX 2019003585 A MX2019003585 A MX 2019003585A MX 2019003585 A MX2019003585 A MX 2019003585A MX 2019003585 A MX2019003585 A MX 2019003585A
- Authority
- MX
- Mexico
- Prior art keywords
- bacterial infections
- compounds
- methods
- negative bacterial
- gram
- Prior art date
Links
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical class C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000027096 gram-negative bacterial infections Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229950006780 n-acetylglucosamine Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente divulgación se refiere a un nuevo compuesto derivado de tetrahidropiridina, a un estereoisómero del mismo o a una sal farmacéuticamente aceptable del mismo, a métodos para preparar 5 los compuestos, a métodos para inhibir UDP-3-O-(R-3-hidroximiristo il)-N-acetilglucosamina desacetilasa (LpxC), a métodos para tratar infecciones bacterianas gramnegativas, al uso de los compuestos para la preparación de medicamentos terapéuticos para tratar infecciones bacterianas gramnegativas y a composiciones farmacéuticas para la 10 prevención o tratamiento de infecciones bacterianas gramnegativas, que contienen los compuestos. Los compuestos representados por la fórmula I, estereoisómeros de los mismos o sales farmacéuticamente aceptables de los mismos de acuerdo con la presente divulgación pueden mostrar excelentes efectos en el tratamiento de infecciones bacterianas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400694P | 2016-09-28 | 2016-09-28 | |
| PCT/KR2017/010896 WO2018062924A1 (en) | 2016-09-28 | 2017-09-28 | Tetrahydropyridine derivatives and their use as antibacterial agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019003585A true MX2019003585A (es) | 2019-06-10 |
| MX379690B MX379690B (es) | 2025-03-11 |
Family
ID=61687790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003585A MX379690B (es) | 2016-09-28 | 2017-09-28 | Derivados de tetrahidropiridina y su uso como agentes antibacterianos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10160724B2 (es) |
| EP (1) | EP3519387B1 (es) |
| JP (1) | JP6812542B2 (es) |
| KR (1) | KR102264248B1 (es) |
| CN (1) | CN110088087B (es) |
| AU (1) | AU2017337946B2 (es) |
| CA (1) | CA3037118C (es) |
| ES (1) | ES2891025T3 (es) |
| MX (1) | MX379690B (es) |
| PL (1) | PL3519387T3 (es) |
| PT (1) | PT3519387T (es) |
| RU (1) | RU2722594C1 (es) |
| WO (1) | WO2018062924A1 (es) |
| ZA (1) | ZA201901945B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3093445A1 (en) | 2018-03-08 | 2019-11-28 | Incyte Corporation | Aminopyrazine diol compounds as pi3k-.gamma. inhibitors |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0311201D0 (en) | 2003-05-15 | 2003-06-18 | Merck Sharp & Dohme | Therapeutic agents |
| WO2009008905A1 (en) * | 2007-02-01 | 2009-01-15 | Panthera Biopharma, Llc. | Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning |
| JP5671545B2 (ja) * | 2009-10-13 | 2015-02-18 | ファイザー・インク | 抗菌薬として有用なｃ結合ヒドロキサム酸誘導体 |
| MX2013011526A (es) * | 2011-04-08 | 2013-12-06 | Pfizer | Derivados de isoxazol utiles como agentes antibacteriales . |
| CN103492368A (zh) * | 2011-04-08 | 2014-01-01 | 辉瑞大药厂 | 用作抗菌剂的咪唑、吡唑和噻唑衍生物 |
| EP2847168A1 (en) * | 2012-05-10 | 2015-03-18 | Achaogen, Inc. | Antibacterial agents |
| JP6514716B2 (ja) * | 2014-04-22 | 2019-05-15 | ノバルティス アーゲー | ＬｐｘＣ阻害剤としてのイソオキサゾリンヒドロキサム酸誘導体 |
| CN106458931A (zh) | 2014-05-16 | 2017-02-22 | 埃科特莱茵药品有限公司 | 抗菌的喹唑啉‑4(3h)‑酮衍生物 |
| RU2018124788A (ru) * | 2015-12-08 | 2020-01-15 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Замещенные бензазиноны в качестве антибактериальных соединений |
-
2017
- 2017-09-28 RU RU2019112881A patent/RU2722594C1/ru active
- 2017-09-28 ES ES17856810T patent/ES2891025T3/es active Active
- 2017-09-28 KR KR1020197012063A patent/KR102264248B1/ko active Active
- 2017-09-28 PL PL17856810T patent/PL3519387T3/pl unknown
- 2017-09-28 CA CA3037118A patent/CA3037118C/en active Active
- 2017-09-28 AU AU2017337946A patent/AU2017337946B2/en active Active
- 2017-09-28 MX MX2019003585A patent/MX379690B/es unknown
- 2017-09-28 PT PT178568101T patent/PT3519387T/pt unknown
- 2017-09-28 EP EP17856810.1A patent/EP3519387B1/en active Active
- 2017-09-28 JP JP2019516938A patent/JP6812542B2/ja active Active
- 2017-09-28 CN CN201780059711.8A patent/CN110088087B/zh active Active
- 2017-09-28 WO PCT/KR2017/010896 patent/WO2018062924A1/en not_active Ceased
- 2017-09-28 US US15/718,474 patent/US10160724B2/en active Active
-
2019
- 2019-03-28 ZA ZA2019/01945A patent/ZA201901945B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110088087B (zh) | 2022-08-09 |
| CA3037118A1 (en) | 2018-04-05 |
| AU2017337946B2 (en) | 2020-05-07 |
| EP3519387B1 (en) | 2021-08-11 |
| ZA201901945B (en) | 2022-07-27 |
| JP2019534252A (ja) | 2019-11-28 |
| JP6812542B2 (ja) | 2021-01-13 |
| WO2018062924A1 (en) | 2018-04-05 |
| US10160724B2 (en) | 2018-12-25 |
| CA3037118C (en) | 2021-12-14 |
| BR112019006129A2 (pt) | 2019-06-18 |
| US20180086709A1 (en) | 2018-03-29 |
| CN110088087A (zh) | 2019-08-02 |
| EP3519387A4 (en) | 2020-05-13 |
| EP3519387A1 (en) | 2019-08-07 |
| KR20190047127A (ko) | 2019-05-07 |
| MX379690B (es) | 2025-03-11 |
| AU2017337946A1 (en) | 2019-04-04 |
| KR102264248B1 (ko) | 2021-06-14 |
| ES2891025T3 (es) | 2022-01-25 |
| NZ751511A (en) | 2020-11-27 |
| PL3519387T3 (pl) | 2022-02-07 |
| PT3519387T (pt) | 2021-09-28 |
| RU2722594C1 (ru) | 2020-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| PH12018500212A1 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| MX2018000916A (es) | Derivados de benzodiazepina como inhibidores de rsv. | |
| BR112018070677A2 (pt) | inibidores de mcl-1 macrocíclicos para o tratamento de câncer | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| CO2021005532A2 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| WO2017123884A8 (en) | Heterocyclic compounds as rsv inhibitors | |
| TN2015000391A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
| BR112015001502A2 (pt) | derivados de tipo azaindazol ou diazaindazol para tratamento de dor | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| BR112019006047A2 (pt) | compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica | |
| MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
| UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| BR112018073524A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição. | |
| SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| UY36124A (es) | Derivados de carboxamida | |
| BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| PH12016501198A1 (en) | Compounds and compositions for the treatment of parasitic diseases |